Cogent Biosciences, Inc. COGT 深 滬
等待開盤 05-30 09:30:00 美东时间
34.96
-0.420
-1.19%
華盛通- 最 高35.52
- 今 開35.52
- 成交量 294.87万股
- 最 低 34.515
- 昨 收 35.38
- 總市值 59.74亿
- 52周最高 43.73
- 市盈率 靜 --
- 換手率 1.73%
- 52周最低 6.59
- 委 比 80.26%
- 總股本 1.71亿
- 歷史最高 43.73
- 量 比 1.21
- 振 幅 2.84%
- 歷史最低 3.67
- 每 手 1
- 風險率 12.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cogent Biosciences Says FDA Accepts NDA For Bezuclastinib In Combination With Sunitinib For Patients With GIST With PDUFA Target Action Date Of November 30
NDA acceptance with Priority Review builds upon previous assignment of Breakthrough Therapy Designation and Real-Time Oncology Review following Phase 3 PEAK results; PDUFA date set for November 30,
05-28 20:21
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $55
HC Wainwright & Co. analyst Robert Burns maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $52 to $55.
05-06 20:06
财报速睇 | Cogent Biosciences, Inc. 2026财年Q1营收0.00亿美元，同比增长0.0%；归母净利润亏损0.97亿美元，同比亏损扩大35.2%
华盛资讯5月5日讯，Cogent Biosciences, Inc.公布2026财年Q1业绩，公司Q1营收0.00亿美元，同比增长0.0%，归母净利润亏损0.97亿美元，同比亏损扩大35.2%。
05-05 20:32
Cogent Biosciences Q1 EPS $(0.53) Beats $(0.56) Estimate
Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.56) by 5.36 percent. This is a 1.92 percent decrease over losses of $(0.52) per share from
05-05 20:24
财报速睇 | Cogent Biosciences, Inc. 2026财年Q1营收0.00亿美元，同比增长0.0%；归母净利润亏损0.97亿美元，同比亏损扩大34.7%
华盛资讯5月5日讯，Cogent Biosciences, Inc.公布2026财年Q1业绩，公司Q1营收0.00亿美元，同比增长0.0%，归母净利润亏损0.97亿美元，同比亏损扩大34.7%。
05-05 20:16
Cogent Biosciences Announces Poster Presentations Of Preclinical Data From The KRAS And ErbB2 Pipeline Programs At The American Association For Cancer Research Meeting, April 17-22
Poster DetailsTitle: Characterization of CGT1263, a KRAS (ON/OFF) inhibitor clinical candidate with selectivity for mutant KRAS over HRAS and NRASSession Category: Experimental and Molecular TherapeuticsSession
04-17 20:05
Cogent Biosciences Files New Drug Application To FDA For Bezuclastinib In Patients With Gastrointestinal Stromal Tumors
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the completion of the submission of its New Drug
04-01 20:06
美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
Cogent Biosciences shares are trading higher after the company announced that the FDA approved its new drug application for bezuclastinib in patients with nonAdvanced systemic mastocytosis.
Cogent Biosciences shares are trading higher after the company announced that t...
03-16 21:03
